SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oral small-molecule biosynthetic ...

This indication is approved based on improvement of NASH and liver scarring (fibrosis). There are ongoing ... the sections appearing in Part I, Item 1A of its Annual Report on Form 10-K for ...

Its lead asset, SFA-002, an IL-10 up-regulator in immune cells, is approaching Phase 2 clinical trials and has shown promising Phase 1a and ... (NASH), with or without fibrosis.

Its lead asset, SFA-002, an IL-10 up-regulator in immune cells, is approaching Phase 2 clinical trial and has shown promising Phase 1a and ... (NASH), with or without fibrosis.

Operator Good day, and welcome to the OPKO Health fourth quarter 2024 financial results conference call. All participants will be in a listen-only mode. [Operator instructions] After today's ...

The Phase 1 portion -- Phase 1a portion of this study is primarily ... non-alcoholic fatty liver disease with improvement in liver fibrosis score. In parallel, we have a collaboration underway ...